3. Dez. 2018OÄ Dr. Sonja Heibl

ASH 2018: „Bei älteren Myelom-Patienten mehr Wert auf das geriatrische Assessment legen.”

OÄ Dr. Sonja Heibl, Abteilung für Innere Medizin IV, Klinikum Wels-Grieskirchen, über die Behandlung von älteren Myelom-Patienten und ihre Take-home-Messages vom ASH 2018 zu MDS und CLL

In diesem Video spricht Frau OÄ Dr. Heibl über folgende, am ASH präsentierte Vorträge:

  • Approach to the Treatment of the Older, Unfit Patient With Myeloma: From Diagnosis to Relapse. Educational Program
  • Fenaux P et al.: The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions, #1
  • Woyach JA et al.: Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202. ASH 2018, #6
  • Shanafelt TD et al.: A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRIN Cancer Research Group (E1912), #LBA-4